Ching‐Yao Yang
National Taiwan University Hospital(TW)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics
Most-Cited Works
- → Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes(2014)287 cited
- → Precision Management of Advanced Non–Small Cell Lung Cancer(2020)197 cited
- → Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma(2016)124 cited
- → High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma(2016)117 cited
- → PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy(2015)98 cited
- → Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors(2019)90 cited
- → Stage Shift Improves Lung Cancer Survival: Real-World Evidence(2022)75 cited
- → CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates(2011)72 cited
- → Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations(2018)63 cited
- → Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer(2020)61 cited